Scholarlink

Deucravacitinib is a first-class, highly selective, oral tyrosine kinase 2 (TYK2) inhibitor, that is approved by the US-FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy/phototherapy. It represents a significant advancement in the treatment of psoriasis and related inflammatory conditions, offering a unique mechanism of action, robust efficacy and a favourable safety profile.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tyrosine Kinase Inhibitors

  • 章节

  • 发表日期：

    2025年

查看全文
  • Aditya Kumar Bubna

摘要

Deucravacitinib is a first-class, highly selective, oral tyrosine kinase 2 (TYK2) inhibitor, that is approved by the US-FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy/phototherapy. It represents a significant advancement in the treatment of psoriasis and related inflammatory conditions, offering a unique mechanism of action, robust efficacy and a favourable safety profile.